The intern will generate DNA sequences to make modified verotoxin proteins that will effectively disrupt the breakdown of a mutant protein (the CFTR protein) that is found in patients with cystic fibrosis. The mutant CFTR protein has normal function but is degraded in cystic fibrosis individuals because of the mutation. The modified verotoxin will reduce the breakdown of the CFTR protein, and hence increase expression of the mutant CFTR protein and subsequent restoration of normal function of cells expressing CFTR protein.
Amorfix Life Sciences has had success producing highly specific antibodies, which can be used to diagnose disease. The company has recently gained access to an algorithm (ProMISTM) which allows to predict antibody targets on proteins in their diseased state, allowing development of very specific antibodies with diagnostic and therapeutic potential. The proposed project involves a comprehensive approach of identifying suitable protein targets involved in disease for the new algorithm by extensive database and market report mining.
Nosocomial infection is a growing problem in Canadian hospitals, these bacteria can kill as many as 8,000 patients per year, and the expenses reach at least $100 million annually. Clostridium difficile (C. difficile) and methicillin‐resistant Staphylococcus aureus (MRSA) are among the most common bacteria. For example, C. difficile has killed more than 600 people in Quebec alone between 2003 and 2005. The control of the spread of bacteria to multiple patients in hospitals and the efficacy of treatment will be improved with early detection of bacteria.
Pharmaceuticals are among the most commonly used and important healthcare treatments in Canada. They are also the second largest single healthcare expenditure and are the fastest increasing healthcare expenditure. For employers, pharmaceuticals are the largest component of their health benefits package and employees cite drugs as being the most valuable part of their employer-funded health benefits.
Amphotericin B is the most effective, and frequently the only treatment available for a number of life-threatening diseases, including systemic fungal infections and visceral leishmaniasis. The drawbacks of today’s amphotericin B treatment are toxicity and the need to administer the drug intravenously in hospital settings. The need for intravenous administration is due to poor absorption of the drug following oral administration and greatly increases the costs of the therapy and complications associated with intravenous admnistration.
Remifentanil, an anesthetic that is administered intravenously during acoustic shock wave treatment for kidney stones, depresses a patient's ability to breathe and can lead to apnea. Respiration is normally detected via standard patient monitors which sound alarms in the event that the patient ceases to breathe for a given length of time. However, a physician or nurse often intervenes before the alarms sound and is able to prompt the patient to breathe properly. The decision to intervene includes visual observation of respiration conditions, and requires vigilant monitoring.
In partnership with Labopharm, a leading company in optimizing the performance of small molecule drugs, a complete pharmacokinetic (PK) study of three new formulations of a commercially available drug will be performed. This study will be conducted in order to choose the most appropriate formulation in terms of bioavailability and absorption rate. Pharmacokinetics parameters of the drug will be estimated using different methods. Mechanisms of drug absorption, distribution, and elimination will also be identified.
Pharmaceuticals are among the most commonly used and important healthcare treatments in Canada. Third party healthcare payers, such as provincial departments of health and private insurers such as Blue Cross and Green Shield, use a variety of tools and techniques to balance the access, cost and quality of medications. Collectively, these tools and techniques are known as drug policies and they include things such as formulary restrictions, prior authorization forms and patient co-payments and deductibles.
The project aims to apply data mining in the VISTA clinical trails database at the Geriatric Medicine Research Unit. The data contains information about Alzheimer’s disease (AD) patients, some of whom received cholinergic treatment and some of whom did not receive this treatment. Because of the variability of responses to treatment as well as the variability in the course of disease progression, it is difficult to identify the patterns robustly associated with improvement, which is crucial in justifying the choice of treatment.
Medication non-compliance is associated with poor outcomes in patients. Although different methods are currently used to measure compliance, the ability to translate this measure into a meaningful metric, which is interpretable for both methodologists and clinicians, has not yet been realized. Medication compliance has become an increasingly important area of research as policy makers perceive the extent and effect of the problem that non-compliance poses.